The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCom.int.bk.regs Regulatory News (CBKD)

Share Price Information for Com.int.bk.regs (CBKD)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.514
Bid: 1.518
Ask: 1.528
Change: 0.002 (0.13%)
Spread: 0.01 (0.659%)
Open: 1.52
High: 1.53
Low: 1.51
Prev. Close: 1.512
CBKD Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

CIB 1st Separate Quarter Results

7 May 2019 07:00

RNS Number : 1051Y
Commercial Intnl Bank (Egypt) SAE
07 May 2019
 

Commercial International Bank (Egypt) S.A.E.

Separate Financial Statements

March 31, 2019

Click on, or paste the following link into your web browser, to view the associated PDF document.http://www.rns-pdf.londonstockexchange.com/rns/1051Y_1-2019-5-5.pdf

 

 

 

 

 

 

 

 

 

 

 

 

 

Separate balance sheet as at March 31,2019

 

 

 

 

 

 

 

 

 

 

Notes

 

 

Mar. 31, 2019

 

 

 

Dec. 31, 2018

 

 

 

 

EGP Thousands

 

 

 

EGP Thousands

 

 

 

 

 

 

 

 

 

Assets

 

 

 

 

 

 

 

 

Cash and balances with central bank

15

 

 

 24,741,584

 

 

 

20,058,974

Due from banks

16

 

 

 51,538,024

 

 

 

46,518,892

Loans and advances to banks, net

18

 

 

241,873

 

 

 

67,703

Loans and advances to customers, net

19

 

 

112,253,470

 

 

 

106,309,205

Derivative financial instruments

20

 

 

 150,424

 

 

 

52,289

Financial investments securities

 

 

 

 

 

 

 

 

- Financial investments securities

21

 

 

 149,898,821

 

 

 

157,585,611

- Investments in associates and subsidiaries

22

 

 

 67,148

 

 

 

68,633

Other assets

23

 

 

10,372,008

 

 

 

9,563,218

Intangible assets

40

 

 

 206,163

 

 

 

238,715

Deferred tax assets (Liabilities)

31

 

 

419,450

 

 

 

308,370

Property, plant and equipment

24

 

 

 1,754,541

 

 

 

1,651,875

Total assets

 

 

 

 351,643,506

 

 

 

342,423,485

 

 

 

 

 

 

 

 

 

Liabilities and equity

 

 

 

 

 

 

 

 

Liabilities

 

 

 

 

 

 

 

Due to banks

25

 

 

3,338,516

 

 

 

7,259,819

Due to customers

26

 

 

293,391,921

 

 

 

285,340,472

Derivative financial instruments

20

 

 

174,198

 

 

 

132,858

Current tax liabilities

 

 

 

1,090,009

 

 

 

3,625,579

Other liabilities

28

 

 

9,989,303

 

 

 

6,501,553

Other loans

27

 

 

3,606,988

 

 

 

3,721,529

Provisions

29

 

 

1,496,939

 

 

 

1,694,607

Total liabilities

 

 

 

313,087,874

 

 

 

308,276,417

 

 

 

 

 

 

 

 

 

Equity

 

 

 

 

 

 

 

 

Issued and paid up capital

30

 

 

14,585,408

 

 

 

11,668,326

Reserves

33

 

 

20,465,557

 

 

 

12,184,667

Reserve for employee stock ownership plan (ESOP)

33

 

 

862,320

 

 

 

738,320

Retained earnings *

33

 

 

2,642,347

 

 

 

9,555,755

Total equity

 

 

 

38,555,632

 

 

 

34,147,068

Total liabilities and equity

 

 

 

351,643,506

 

 

 

342,423,485

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The accompanying notes are an integral part of these financial statements.

 

 

 

 

 

 

 

(Review report attached)

 

 

 

 

 

 

 

 

*Including net profit for the current period

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Separate income statement for the period ended March 31, 2019

 

 

 

 

 

 

 

 

 

 

 

Note

Mar. 31, 2019

 

 

Mar. 31, 2018

 

 

 

EGP Thousands

 

 

EGP Thousands

 

 

 

 

 

 

 

Interest and similar income

 

 

10,278,050

 

 

7,936,316

Interest and similar expense

 

 

(5,339,464)

 

 

(4,676,400)

Net interest income

 

6

4,938,586

 

 

3,259,916

 

 

 

 

 

 

 

Fee and commission income

 

 

855,477

 

 

786,422

Fee and commission expense

 

 

(277,625)

 

 

(214,083)

Net fee and commission income

 

7

577,852

 

 

572,339

 

 

 

 

 

 

 

Dividend income

 

8

121

 

 

1,086

Net trading income

 

9

249,879

 

 

436,092

Profits (Losses) on financial investments

 

21

6,377

 

 

146,651

Administrative expenses

 

10

(1,320,672)

 

 

(957,074)

Other operating (expenses) income

 

11

(141,097)

 

 

(236,859)

Intangible assets amortization

 

40

(32,552)

 

 

(32,552)

Impairment charge for credit losses

 

12

(520,727)

 

 

(320,232)

Profit before income tax

 

 

3,757,767

 

 

2,869,367

 

 

 

 

 

 

 

Income tax expense

 

13

(1,090,009)

 

 

(896,492)

Deferred tax assets (Liabilities)

 

31 - 13

(25,411)

 

 

44,763

Net profit for the period

 

 

2,642,347

 

 

2,017,638

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earning per share

 

14

 

 

 

 

Basic

 

 

1.63

 

 

1.25

Diluted

 

 

1.62

 

 

1.24

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

         

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Separate statement of other comprehensive income for the period ended March 31, 2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Notes

Mar. 31, 2019

 

Mar. 31, 2018

 

EGP Thousands

 

EGP Thousands

 

 

 

 

 

Net profit for the period

 

2,642,347

 

2,017,638

Reserve for financial assets at fair value through OCI

 

2,335,582

 

(603,484)

Total other comprehensive income for the period

 

4,977,929

 

1,414,154

 

 

 

 

 

 

 

 

 

 

Separate cash flow for the period ended March 31, 2019

 

Notes

Mar. 31, 2019

 

Mar. 31, 2018

 

 

EGP Thousands

 

EGP Thousands

 

 

 

 

 

Cash flow from operating activities

 

 

 

 

Profit before income tax

 

3,757,767

 

2,869,367

Adjustments to reconcile net profit to net cash provided by operating activities

 

 

 

 

Fixed assets depreciation

24

131,898

 

94,089

Impairment charge for credit losses

12

634,951

 

320,232

Other provisions charges

29

2,077

 

26,048

Provisions charges - due from banks

12

(7,102)

 

-

Provisions charges - financial investments

12

(107,122)

 

-

Impairment charge for other assets

23

24,814

 

-

Exchange revaluation differences for financial assets at fair value through OCI

21

334,394

 

39,053

Intangible assets amortization

40

32,552

 

32,552

Impairment charge financial assets at fair value through OCI

21

45,664

 

(16)

Exchange differences in financial investments in subidiary

22

1,485

 

209

Utilization of other provisions

29

2,461

 

245

Other provisions no longer used

29

(164,335)

 

-

Exchange differences of other provisions

29

(37,871)

 

2,578

(Profits) losses from selling financial investments

21

(52,041)

 

(146,635)

Shares based payments

 

124,000

 

107,302

Operating profits before changes in operating assets and liabilities

 

4,723,592

 

3,345,024

 

 

 

 

 

 

 

 

 

 

Net decrease (increase) in assets and liabilities

 

 

 

 

Due from banks

16

(17,549,341)

 

(29,978,825)

Treasury bills and other governmental notes

41

15,781,350

 

8,624,987

Financial assets at fair value through P&L

21

2,180,287

 

124,989

Derivative financial instruments

20

(47,159)

 

(5,392)

Loans and advances to banks and customers

18 - 19

(6,035,057)

 

(7,195,719)

Other assets

42

(587,120)

 

(1,232,913)

Due to banks

25

(3,921,303)

 

9,474,440

Due to customers

26

8,051,449

 

5,354,264

Income tax obligations paid

 

(3,762,070)

 

(2,778,973)

Other liabilities

28

3,487,750

 

2,608,087

Net cash provided from operating activities

 

2,322,378

 

(11,660,031)

 

 

 

 

 

Cash flow from investing activities

 

 

 

 

Payment for purchases of subsidiary and associates

 

-

 

(10,575)

Payment for purchases of property, plant, equipment and branches constructions

 

(483,048)

 

(214,488)

Proceeds from redemption of financial assets at amortized cost

21

33,452,378

 

2,808,013

Payment for purchases of financial assets at amortized cost

21

(32,834,360)

 

-

Payment for purchases of financial assets at fair value through OCI

21

(4,493,603)

 

(10,484,844)

Proceeds from selling financial assets at fair value through OCI

 

4,617,766

 

303,449

Net cash used in investing activities

 

259,133

 

(7,598,445)

 

 

 

 

 

Separate cash flow for the period ended March 31, 2019 (Cont.)

 

 

 

 

 

 

Mar. 31, 2019

 

Mar. 31, 2018

 

 

EGP Thousands

 

EGP Thousands

Cash flow from financing activities

 

 

Increase in long term loans

27

(114,541)

13,092

Dividend paid

 

(2,700,544)

(2,143,177)

Net cash used in (provided from) financing activities

 

(2,815,085)

(2,130,085)

 

 

 

 

 

 

Net increase (decrease) in cash and cash equivalent during the period

 

(233,574)

(21,388,561)

Beginning balance of cash and cash equivalent

 

34,303,645

49,208,837

Cash and cash equivalent at the end of the period

 

34,070,071

27,820,276

 

 

 

 

 

 

 

Cash and cash equivalent comprise:

 

 

Cash and balances with central bank

15

24,741,584

26,182,232

Due from banks

16

51,538,237

42,306,844

Treasury bills and other governmental notes

17

33,831,714

45,937,458

Obligatory reserve balance with CBE

15

(17,837,693)

(20,421,756)

Due from banks with maturities more than three months

 

(23,971,797)

(20,155,641)

Treasury bills with maturity more than three months

 

(34,231,974)

(46,028,861)

Total cash and cash equivalent

 

34,070,071

27,820,276

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Separate statement of changes in shareholders' equity for the period ended March 31, 2018

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Mar. 31, 2018

Issued and paid up capital

Legal reserve

General reserve

General risk reserve*

Special reserve

Capital reserve

Reserve for financial assets at fair value through OCI

Banking risks reserve

IFRS 9 risk reserve

Retained earnings

Reserve for employee stock ownership plan

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Beginning balance

11,618,011

1,332,807

9,000,023

-

20,645

11,815

(1,642,958)

3,634

1,411,549

6,138,790

489,334

28,383,650

 

 

 

 

 

Transferred to reserves

-

377,486

3,616,832

-

-

606

-

-

-

(3,994,924)

-

-

 

 

 

 

 

Dividend paid

-

-

-

-

-

-

-

-

-

(2,143,177)

-

(2,143,177)

 

 

 

 

 

Net profit for the period

-

-

-

-

-

-

-

-

-

2,017,638

-

2,017,638

 

 

 

 

 

Net unrealised gain/(loss) on financial assets at fair value through OCI

-

-

-

-

-

-

(603,484)

-

-

-

-

(603,484)

 

 

 

 

 

Transferred (from) to bank risk reserve

-

-

-

-

-

-

-

689

-

(689)

-

-

 

 

 

 

 

Cost of employees stock ownership plan (ESOP)

-

-

-

-

-

-

-

-

-

-

107,302

107,302

 

 

 

 

 

Balance at the end of the period

11,618,011

1,710,293

12,616,855

-

20,645

12,421

(2,246,442)

4,323

1,411,549

2,017,638

596,636

27,761,929

 

 

 

 

 

                   

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Separate statement of changes in shareholders' equity for the period ended March 31, 2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Mar. 31, 2019

Issued and paid up capital

Legal reserve

General reserve

General risk reserve*

Special reserve

Capital reserve

Reserve for financial assets at fair value through OCI

Banking risks reserve

IFRS 9 risk reserve

Retained earnings

Reserve for employee stock ownership plan

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Beginning balance

11,668,326

1,710,293

12,776,215

-

20,645

12,421

(3,750,779)

4,323

1,411,549

9,555,755

738,320

34,147,068

 

 

 

 

Effect of applying IFRS 9**

-

-

-

117,251

-

-

1,889,928

-

-

-

-

2,007,179

 

 

 

 

Transferred to general risk reserve

-

-

-

1,432,194

(20,645)

-

-

-

(1,411,549)

-

-

-

 

 

 

 

Beginning balance after the impact of initial application

11,668,326

1,710,293

12,776,215

1,549,445

-

12,421

(1,860,851)

4,323

-

9,555,755

738,320

36,154,247

 

 

 

 

Capital increase

2,917,082

-

(2,917,082)

-

-

-

-

-

-

-

-

-

 

 

 

 

Transferred to reserves

-

477,736

6,375,589

-

-

1,045

-

-

-

(6,854,370)

-

-

 

 

 

 

Dividend paid

-

-

-

-

-

-

-

-

-

(2,700,544)

-

(2,700,544)

 

 

 

 

Net profit for the period

-

-

-

-

-

-

-

-

-

2,642,347

-

2,642,347

 

 

 

 

Net unrealised gain/(loss) on financial assets at fair value through OCI

-

-

-

-

-

-

2,442,704

-

-

-

-

2,442,704

 

 

 

 

Transferred (from) to bank risk reserve

-

-

-

-

-

-

-

841

-

(841)

-

-

 

 

 

 

Provision for impairment of debt instruments investments

-

-

-

 

-

-

(107,122)

-

-

-

-

(107,122)

 

 

 

 

Cost of employees stock ownership plan (ESOP)

-

-

-

-

-

-

-

-

-

-

124,000

124,000

 

 

 

 

Balance at the end of the period

14,585,408

2,188,029

16,234,722

1,549,445

-

13,466

474,731

5,164

-

2,642,347

862,320

38,555,632

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

\* The special reserve, general bank risk reserve and IFRS 9 risk reserve - were consolidated in the general risk reserve as per the instructions of the Central Bank of Egypt dated 26 February 2019

 

 

 

 

 

 

 

 

 

 

The initial application impact (disclosure in page number 15)**

 

 

 

 

 

 

 

 

 

The initial application impact is LE 109,697 thousand and the tax effect is LE 7,554 thousand

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
QRFUVSRRKUAVRUR
Date   Source Headline
26th Mar 20247:49 amRNSChanges in CIB's BOD - 25 March 2024
26th Mar 20247:00 amRNSOGM Resolutions - March 25th, 2024
26th Mar 20247:00 amRNSEGM Resolutions - March 25th, 2024
20th Feb 20247:00 amRNSNotice of AGM
20th Feb 20247:00 amRNSInvitation to Extraordinary GM (EGM)
16th Nov 20233:45 pmRNSCIB secures a USD 150M subordinated loan from EBRD
3rd Nov 20237:05 amRNS3Q23 Earnings Release
3rd Nov 20237:05 amRNS3rd Quarter Results
3rd Nov 20237:05 amRNS3rd Quarter Results - Consolidated
23rd Aug 20237:14 amRNSAppointment of Mr. Jawaid Mirza in CIB's BOD
24th Jul 20238:00 amRNSCIB 1H2023 Earnings Release
24th Jul 20238:00 amRNSCIB1H2023 Condensed Consolidated Financials
24th Jul 20238:00 amRNSCIB 1H2023 Separate Condensed Financial Statements
10th Jul 20238:00 amRNSCIB obtaining Long term loans from IFC
15th May 20237:00 amRNSCIB 1Q23 - Earnings Release
15th May 20237:00 amRNSCIB Q1-2023 Separate Financial Statements
15th May 20237:00 amRNSCIB 1Q23 Consolidated Financial Statements
20th Mar 20236:26 pmRNSCIB's FY22 IFRS 9 Financial Statements
20th Mar 20235:02 pmRNSResolutions Extraordinary General Assembly
20th Mar 20234:55 pmRNSResolutions Ordinary General Assembly (OGM)
16th Feb 20237:00 amRNSInvitation to CIB's Ordinary General Assembly
16th Feb 20237:00 amRNSInvitation to CIB's Extraordinary General Assembly
13th Feb 20237:00 amRNSCIB - 4Q 2022 Earnings Release
13th Feb 20237:00 amRNSCIB Q4-2022 Separate Financial Statements
13th Feb 20237:00 amRNSCIB Q4-2022 Consolidated Financial Statements
30th Jan 20237:00 amRNSCIB fully acquires MayFair CIB (Kenya)-Replacement
27th Jan 20235:51 pmRNSCIB fully acquires Mayfair CIB
11th Jan 20234:41 pmRNSSecond Price Monitoring Extn
11th Jan 20234:35 pmRNSPrice Monitoring Extension
8th Dec 202212:25 pmRNSPress Release dated 8 December 2022
22nd Nov 20228:14 amRNSChanges in CIB's Board of Directors
4th Nov 20227:00 amRNS3rd Quarter 2022 (Earnings Release)
4th Nov 20227:00 amRNSBoard Resolutions Summary 3 Nov 2022
4th Nov 20227:00 amRNS3rd Quarter 2022 Results (Separate)
4th Nov 20227:00 amRNS3rd Quarter 2022 Results (Consolidated)
15th Aug 20227:00 amRNSChange in CIB's CEO Retail Banking
25th Jul 20227:00 amRNSCIB 1H2022 Condensed Separate Financial Results
25th Jul 20227:00 amRNSCIB1H2022 Earnings Release
25th Jul 20227:00 amRNSCIB1H2022 Consolidated Condensed Financial Results
19th May 20223:09 pmRNSChange in CIB's Board of Directors
29th Apr 202212:17 pmRNSCIB FY 2021 IFRS Annual Financial Report
19th Apr 20227:00 amRNSCIB 1Q2022 Earnings Release
19th Apr 20227:00 amRNSCIB1Q2022 Condensed Consolidated Financial results
19th Apr 20227:00 amRNSCIB 1Q2022 Condensed Separate Results
28th Mar 20227:00 amRNSCIB's AGM Resolutions Summary
10th Mar 20224:41 pmRNSSecond Price Monitoring Extn
10th Mar 20224:36 pmRNSPrice Monitoring Extension
9th Mar 20224:36 pmRNSPrice Monitoring Extension
4th Mar 20227:00 amRNSInvitation toCIB Ordinary General Assembly Meeting
22nd Feb 20227:00 amRNSCIB FY 2021 Separate Financial results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.